2. Signalwege
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

ADC-Related Custom Services

Drug-Linker Conjugates for ADC

Related Products

PDF 0.45 MB

Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.

The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.

ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.

Drug-Linker Conjugates for ADC Isoform Specific Products:

Drug-Linker Conjugates for ADC Isoform Comparison
Art. -Nr. Produktname Wirkung Reinheit Chemical Structure
  • HY-148459
    ATAC21
    ATAC21, a linker-immune-stimulatory compound that can be formed by conjugating a noncleavable maleimide-PEG4 linker containing a succinimide group with an immune- stimulatory compound. ATAC21 can be combined with SBT-040 (anti-CD40 antibody) to form a conjugate.
    ATAC21
  • HY-148380
    Mal-PEG8-Phe-Lys-PAB-Exatecan
    Mal-PEG8-Phe-Lys-PAB-Exatecan (compound 15) is a agent-linker conjugate for ADC, composed of degradable linker Mal-PEG8-Phe-Lys-PAB and toxin molecule Exatecan (HY-13631) composition.
    Mal-PEG8-Phe-Lys-PAB-Exatecan
  • HY-164163
    MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT
    MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT (example 4-3) is an ADC drug-linker conjugate composed of an payload 7-MAD-MDCPT (HY-132162) and a linker MP-PEG8-Val-Lys-Gly (HY-179261), used for synthesizing ADC.
    MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT
  • HY-179327
    N-(Hexanoyloxy)succinimide-MMAE
    N-(Hexanoyloxy)succinimide-MMAE is a conjugate of the ADC drug toxin molecule and the linker, containing a degradable PEG linker and the toxin molecule MMAE (HY-15162).
    N-(Hexanoyloxy)succinimide-MMAE
  • HY-142740
    Rha-PEG3-SMCC
    Rha-PEG3-SMCC (compound 13) is a agent-linker conjugate for ADC with potent antitumor activity by using SMCC (a protein crosslinker), linked via the noncleavable ADC linker Rha-PEG3.
    Rha-PEG3-SMCC
  • HY-176807
    DBCO-HS-PEG2-VA-PABC-SG3199
    DBCO-HS-PEG2-VA-PABC-SG3199 is a drug-linker conjugate for ADC. DBCO-HS-PEG2-VA-PABC-SG3199 consists of a SG3199 (HY-101161) based DNA small channel crosslinker and cleavable linker. DBCO-HS-PEG2-VA-PABC-SG3199 can be used for synthesis of ADCs.
    DBCO-HS-PEG2-VA-PABC-SG3199
  • HY-178289
    Fmoc-Val-Lys(Boc)-PAB-Exatecan
    Fmoc-Val-Lys(Boc)-PAB-Exatecan (Compound 39-7) is a Drug-Linker Conjugates for ADC. Fmoc-Val-Lys(Boc)-PAB-Exatecan consists of the ADC Cytotoxin Exatecan (HY-13631) and a linker PAB-Val-Lys-Boc (HY-138651). Fmoc-Val-Lys(Boc)-PAB-Exatecan can be used for synthesis of ADCs.
    Fmoc-Val-Lys(Boc)-PAB-Exatecan
  • HY-148227
    Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB-MMAE
    Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB-MMAE (Compound 31) is a Drug-Linker Conjugates for ADC. Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB-MMAE is composed of MMAE (HY-15162) and Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB carbonic acid (HY-171663) .
    Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB-MMAE
  • HY-179659
    STING agonist-49-β-D-Glu-benzylalcohol-di(amide-C2)-mal
    STING agonist-49-β-D-Glu-benzylalcohol-di(amide-C2)-mal (compound gluc-cSTING linker-payload) is a drug-linker conjugate for ADC. STING agonist-49-β-D-Glu-benzylalcohol-di(amide-C2)-mal can be used for ADC synthesis.
    STING agonist-49-β-D-Glu-benzylalcohol-di(amide-C2)-mal
  • HY-128979B
    Deruxtecan analog 2 monoTFA
    		99.56%
    Deruxtecan analog 2 (monoTFA) is a homolog of Deruxtecan (HY-13631E), a conjugate of the ADC toxin DX-8951 derivative (Dxd) with an ADC Linker.
    Deruxtecan analog 2 monoTFA
  • HY-177307
    Mal-Val-Lys-PAB-MMAE
    Mal-Val-Lys-PAB-MMAE is a drug-linker conjugate for ADC. Mal-Val-Lys-PAB-MMAE consists of a Tubulin inhibitor (MMAE) (HY-15162) and a linker (Mal-Val-Lys-PAB). Mal-Val-Lys-PAB-MMAE can be used for synthesis of ADCs.
    Mal-Val-Lys-PAB-MMAE
  • HY-185577
    MMAE-PAB-Gyykr
    MMAE-PAB-Gyykr is a drug-linker conjugate for ADC, consisting of a cleavable ADC linker (Arg-Lys-Tyr-Tyr-Gly) and a potent tubulin inhibitor Monomethyl auristatin E (MMAE) (HY-15162). MMAE-PAB-Gyykr can be used in the synthesis of antibody-drug conjugates (ADCs).
    MMAE-PAB-Gyykr
  • HY-147231
    SG3400 delate(Mal-amido-PEG8)
    SG3400 delate (Mal-amido-PEG8) (compound 21) is an intermediate for the synthesis of ADC molecules. SG3400 delete is an effective toxin molecule with anticancer activity. SG3400 delete can be used in cancer research.
    SG3400 delate(Mal-amido-PEG8)
  • HY-177684
    N-(endo-BCN-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan)
    N-(endo-BCN-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(endo-BCN-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
    N-(endo-BCN-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan)
  • HY-175216
    Maleimide-Ph(3,5-F)-PEG4-Val-Ala-MF-6
    Maleimide-Ph(3,5-F)-PEG4-Val-Ala-MF-6 is a drug-linker conjugate for ADC. Maleimide-Ph(3,5-F)-PEG4-Val-Ala-MF-6 consists of a topoisomerase 1 inhibitor (Topi MF-6) (HY-175203) and a cleavable linker (Maleimide-Ph(3,5-F)-PEG4-Val-Ala) (HY-175218). Maleimide-Ph(3,5-F)-PEG4-Val-Ala-MF-6 can be used for synthesis of ADCs.
    Maleimide-Ph(3,5-F)-PEG4-Val-Ala-MF-6
  • HY-156514
    MC-GGFG-AM-(10NH2-11F-Camptothecin)
    MC-GGFG-AM-(10NH2-11F-Camptothecin) is an antibody drug conjugates (ADC). MC-GGFG-AM-(10NH2-11F-Camptothecin) binds to the anti-TROp-2 antibody sacituzumab via a hydrolysable pH-sensitive linker and has anti-tumor activity. MC-GGFG-AM-(10NH2-11F-Camptothecin) can be used for cancer research.
    MC-GGFG-AM-(10NH2-11F-Camptothecin)
  • HY-182813
    MC-amide-C2-amide-(β-D-GlcUA)-amide-PEG1-CH2-CC-885
    MC-amide-C2-amide-(β-D-GlcUA)-amide-PEG1-CH2-CC-885 is a Drug-Linker Conjugates for ADC composed of CC-885 (HY-101488) and a linker. MC-amide-C2-amide-(β-D-GlcUA)-amide-PEG1-CH2-CC-885 conjugates with GemtUZUmab (HY-P99971) to synthesize an ADC (Compound ADC-2). ADC-2 exhibits anti-tumor activity in a leukemia MV-4-11 xenograft model.
    MC-amide-C2-amide-(β-D-GlcUA)-amide-PEG1-CH2-CC-885
  • HY-185569
    DM21-L-G NHS ester
    DM21-L-G NHS ester is a toxin molecule-linker conjugate that can be used for the synthesis of ADCs, such as Opugotamig olatansine (HY-185427).
    DM21-L-G NHS ester
  • HY-144554
    Aminooxy CatB-LXR
    Aminooxy CatB-LXR (compound 10) is a agent-linker conjugates for ADC.
    Aminooxy CatB-LXR
  • HY-181697
    SDP-LIV1 drug-linker
    SDP-LIV1 drug-linker is a drug-linker conjugate formed by the condensation of a linker and a topoisomerase I inhibitor. It can be used for the preparation of ADCs, such as SDP-LIV1.
    SDP-LIV1 drug-linker
Drug-Linker Conjugates for ADC Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.